West Island Brands - CEO, Boris Ziger
CEO, Boris Ziger
Source: Small Cap Power
  • A Matica (CSE:MMJ) subsidiary has signed a purchase agreement with a Franchise Cannabis subsidiary to acquire cannabis genetic material
  • Through the agreement, Matica’s RoyalMax Biotechnology will obtain THC varieties from Franchise’s Rangers Pharmaceuticals
  • Franchise Cannabis has a collection of over 220 cannabis strains, kept within the first legally registered seedbank in Europe
  • The varieties include Wakeford, Pineapple Express, and Triumphant.
  • Matica (MMJ) is up 25.00 per cent, and is currently trading for 2.5 cents per share

A Matica (CSE:MMJ) subsidiary has signed a purchase agreement with a Franchise Cannabis subsidiary to acquire cannabis genetic material.

The company’s RoyalMax Biotechnology Canada entered the agreement with Franchise’s Rangers Pharmaceuticals. 

Through the purchase agreement, RoyalMax will obtain high-THC varieties from Franchise’s seedbank, the first legally registered one in Europe. The varieties include Wakeford, Pineapple Express, and Triumphant, which Matica expects will receive a warm welcome in Canada.

Franchise Cannabis has over 220 diverse cannabis strains, bred by world-renowned breeder Charles Scott.

He has previously won several awards for his THC strains, such as Love Potion #1, Willie Nelson, and Pink Kush. He has also won 19 Cannabis Cups, and been inducted into the High Times Hall of Fame.  

Matica believes that it will gain a new competitive advantage by injecting new, exciting cannabis strains into Canada’s market.

Matica’s CEO, Boris Ziger, welcomed the opportunities which the purchase agreement brings.

“RoyalMax will introduce new cannabis varieties unique to the Canadian market. Currently there is a lack of genetic diversity within the Canadian market. 

“RoyalMax will have the ability to offer new and unique product varieties to our consumers. Through this relationship, RoyalMax will benefit from one of the most complete and sought-after genetics collections in the world,” he said.

Franchise Cannabis’ CEO, Clifford Starke, also commented on the agreement.

“Matica will have a distinct advantage within the Canadian market by utilizing some of our top strains, such as the highly unique and potent Triumphant, which have not yet been introduced to the Canadian market.

“Franchise is excited to fill this gap and work with innovators in the industry, such as Matica, to effectively cultivate and distribute product based on our unique cultivars,” he said.

Matica (MMJ) is up 25.00 per cent, and is trading for 2.5 cents per share, at 11:59am EDT.

More From The Market Online

Rapid Dose Therapeutics collaborates with NFL

Rapid Dose Therapeutics (CSE:DOSE) reveals a collaboration with the National Football League (NFL) for a funded clinical trial program.

The Market Online’s Weekly Cannabis Report – May 24, 2024

A global cannabis stock intends to raise up to US$250 million through an at-the-market equity program to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.